Loading the company…
Loading the company…
Families: Coronary intervention (PCI), Peripheral arterial intervention.
All companies · Product and company coverage
In the last ten years FDA made 6 decisions for Orbusneich Medical Shenzhen (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2024 (3). The latest was on 2024-08-16.
| Family | Decisions on record |
|---|---|
| Coronary intervention (PCI) | 3 |
| Peripheral arterial intervention | 3 |
| JADE |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Orbusneich Medical Shenzhen.